-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $49

Benzinga·02/26/2026 18:48:40
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $47 to $49.